MedTrace Logo

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

NCT05620017 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2026-02-09

No results posted yet for this study

Summary

Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

Conditions

Interventions

DRUG

BAT8008 for Injection

Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Sponsors & Collaborators

Principal Investigators

  • Weier Song · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620017 on ClinicalTrials.gov